<DOC>
	<DOCNO>NCT01385891</DOCNO>
	<brief_summary>Study Hypothesis . combination chemotherapy Clofarabine VP16 Cyclophosphamide able induce remission resistant/refractory acute leukemia pediatric . Forty child relapse refractory Acute Lymphoblastic Leukemia ( ALL ) Acute Myeloid Leukemia ( AML ) enter study receive association clofarabine ( 40 mg/m2/day ) combination etoposide ( 100 mg/m2/day ) Cyclophosphamide ( 440 mg/m2/day ) 1 2 induction cycle End point complete remission ( CR ) CR without platelet recovery ( CRp ) toxicity</brief_summary>
	<brief_title>Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>presence &gt; 25 % blast bone marrow treatment second line therapy patient resistant disease i.e . &gt; 25 % blast 21 day last cytostatic agent administration child persistent high MRD level ( &gt; 103 ) first line chemotherapy , consider eligible treatment Relapsed &gt; month SCT Karnofsky score &gt; 50 Forced Espiratory Volume &gt; 30 % sufficient hepatic renal function define creatinine level &lt; 2 × ULN , bilirubin &lt; 1.5 × ULN aspartate alanine aminotransferase &lt; 10 × ULN . isolate extramedullary relapse , active infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>